![Nizar Jacques Bahlis: A plea (and not a criticism) to myeloma community to heavily invest in genomic, immunogenomic and biomarkers studies](https://oncodaily.com/pub/uploads/2023/09/Lu2hhFt7_400x400-e1710531961665-1280x961.jpg)
Photo taken from Nizar Jacques Bahlis/Twitter
Mar 15, 2024, 15:46
Nizar Jacques Bahlis: A plea (and not a criticism) to myeloma community to heavily invest in genomic, immunogenomic and biomarkers studies
Nizar Jacques Bahlis, Associate Professor of Medicine at the University of Calgary, posted on X:
“SMM: Taking the narrow over the wide path. This is a plea (and not a criticism) to the myeloma community to heavily invest in genomic, immunogenomic & biomarkers studies to generate better classifiers of risk of progression or redefine SMM (Smoldering multiple myeloma) as MGUS or MM.”
Read Further.
Source: Nizar Jacques Bahlis/ X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023